Andere talen Luye Pharma Group Ltd.

Aandelen

2186

BMG570071099

Farmaceutische producten

Beurs gesloten - Hong Kong S.E. Andere beurzen 09:08:15 17-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,010 ^HKD	0,00%		-1,95%	-7,37%

16/01	Luye Pharma Group neemt eerste patiënt op in Fase II Studie voor nieuw medicijn tegen de ziekte van Huntington	MT
15/01	Luye Pharma Group Ltd. Kondigt de eerste patiëntenregistratie aan voor de Fase 2 Klinische Studie van het Nieuwe Geneesmiddel LY03015 van de Groep in China	CI

Andere talen

Luye Pharma Group Enrolls First Patient in Phase II Trial for New Huntington's Disease Drug	16/01
Luye Pharma Group Ltd. Announces First Patient Enrollment for the Phase 2 Clinical Study of the Group's New Drug LY03015 in China	15/01
Luye Pharma : Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.	15/01
Luye Pharma Gets US FDA Approval for Clinical Trials for Schizophrenia Drug	15/01
Luye Pharma Group Ltd. Announces Approval for the Group's New Drug LY03020 for Clinical Trials in the U.S	14/01
Luye Pharma Group Issues $50 Million Convertible Bonds	16/12
Luye Pharma Files for Singapore Listing of $50 Million of Bonds Due in 2025	13/12
PharmaMar's Zepzelca receives approval in China for the treatment of small cell lung cancer	04/12
PharmaMar's Lung Cancer Therapy Gets Regulatory Approval in China	03/12
Luye Pharma Gets Marketing Go-Ahead for Lung Cancer Drug from Chinese Regulator	03/12
Luye Pharma Group Ltd. Announces Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland China	03/12
Three Luye Pharma Products Included in National Reimbursement Drug List	28/11
Luye Pharma : Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China	11/11
Luye Pharma's Anti-Depression Drug Gets IND Approval in China	11/11
Luye Pharma Group Ltd. Announces Approval for Class 1 Innovative Antibody LY03021 for Clinical Trials in China	11/11
Luye Pharma Group Raises Nearly $99 Million via Bonds Issue	31-10-24
Luye Pharma Group Files for Singapore Listing of $100 Million Bonds Due 2025	30-10-24
Luye Pharma Group to Issue $150 Million Convertible Bonds in Two Tranches	23-10-24
Luye Pharma Group's H1 Profit Up By 159%	30-09-24
Luye Pharma : Announces 2024 Half Year Results	29-08-24
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	28-08-24
Luye Pharma : mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China	13-08-24
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan	13-08-24
China Approves Luye Pharma's Anti-Psychotic Drug for Trials; Shares Jump 5%	06-08-24
Luye Pharma : Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China	06-08-24

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Luye Pharma Group Ltd.

Aandelen

2186

BMG570071099

Farmaceutische producten

Andere talen

Filters